Navigation Links
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia
Date:11/6/2007

r injection 7.5 mg/mL. In adult patients, the recommended ABILIFY oral target dose is 15 mg to 30 mg/day in Bipolar I Disorder and 10 mg to 15 mg/day in schizophrenia. In adolescent patients with schizophrenia, the recommended ABILIFY oral target dose is 10 mg/day (with a starting dose of 2 mg/day which was titrated to 5 mg after 2 days and to the target dose of 10 mg after 2 additional days). The 30 mg/day dose was not shown to be more efficacious than the 10 mg/day dose. In adult patients with agitation associated with bipolar mania or schizophrenia, the ABILIFY Injection initial dose is 9.75 mg/1.3 mL. If ongoing ABILIFY therapy is clinically indicated, oral ABILIFY in a range of 10 mg to 30 mg/day should replace ABILIFY Injection as soon as possible. The safety of doses of ABILIFY oral or ABILIFY Injection above 30 mg/day has not been evaluated in clinical trials.

IMPORTANT SAFETY INFORMATION and INDICATIONS for ABILIFY

INDICATIONS:

-- ABILIFY is indicated for acute and maintenance treatment of

schizophrenia in adults

-- ABILIFY is indicated for the treatment of schizophrenia in adolescents

13 to 17 years of age

-- ABILIFY is indicated for acute and maintenance treatment of bipolar

disorder with or without psychotic features

ABILIFY Injection is indicated for the treatment of adults with agitation associated with schizophrenia or bipolar disorder, manic or mixed.

IMPORTANT SAFETY INFORMATION:

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. ABILIFY is not approved for the treatment of patients with dementia-related psychosis (see Boxed WARNING).

Cerebrovascular adverse events (eg, stroke, transient ischemic attack),

including fatalities, have been reported at an increased incidence in

clinical trials of elderly patients with dementia-related psychosis

treate
'/>"/>

SOURCE Otsuka Pharmaceutical Co., Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
2. Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees
3. Wells Fargo Offers Online Benefit Administration for Business and Individual Healthcare Consumers
4. Administration Anesthetized to Ailments of Nations Children
5. Supratek Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SP1049C for the treatment of metastatic adenocarcinoma of the upper gastrointestinal tract
6. Siemens Medical Solutions Receives CCHIT Certification for Soarian Clinicals With Siemens Pharmacy and Med Administration Check
7. FDA Approves First Anti-Psychotic for Kids
8. FDA Approves New Roche West Nile Virus Blood Screening Test
9. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
10. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
11. FDA Approves SOMA(R) (carisoprodol) 250 mg
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... The American Society of ... engaged in the field of organ transplantation, today ... Immunology Research Network (TIRN), a professional network ... modern organ transplantation continues to diversify, AST determined ... more opportunities for physicians, scientists and researchers to ...
(Date:7/28/2014)... one of the UK,s most common respiratory diseases has ... disease (COPD) is the name for a collection of ... to the lungs. Often linked to smoking, it ... admissions in the UK, with a high proportion of ... , A team of researchers, led by ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 With California ... it is welcome news that a fire blanket ... current protection is under development by SunSeeker Enterprises, Inc. ... to protect spacecraft from the extreme heat of re-entry ... both firefighters and homes. , “Our firefighters routinely lay ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Drorit Silverman, ... unveiled new plans to raise investment capital through her ... fitness concept in the United States. , According to ... of 24/7 fitness centers provide a great window of ... rapidly expanding space. In addition to this, Silverman looks ...
(Date:7/28/2014)... Medicine (BUSM) report variants in a new gene, PLXNA4, ... (AD). The discovery of this novel genetic association may ... specifically. These findings appear in the Annals of ... dementia affecting 5.4 million Americans including 13 percent of ... percent of people age 85 and older. Genetic factors ...
Breaking Medicine News(10 mins):Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Pro Bodybuilder Drorit Silverman Confirms Plans to Raise Money for Investment in the Popular 24/7 Fitness Concept 2Health News:Researchers identify potential biomarker for AD 2
... Community,in partnership with the Forum, Unveil Disease "Hot Spots" ... (KCP) - an alliance of patient advocates, ... improve quality of care for individuals with kidney disease ... regarding the racial disparity among those suffering from Chronic ...
... Sysmex America, Inc., a leading medical diagnostic instrument ... availability of the Sysmex WAM eLearning program to ... across the U.S. Sysmex WAM eLearning gives customers ... Sysmex WAM users and as a tool to ...
... entitled Motorcycle Cancer? is sending a ... seat extremely low frequency electromagnetic field (ELF EMF) ... Randall Dale Chipkar. "Science proves electromagnetic danger and ... read up to 500 milliGauss of ELF EMF ...
... PLC Systems Inc. (OTC Bulletin Board: PLCSF) announced today ... financial results for the fourth quarter and year ended December ... 2009. The company plans to host a conference call to ... day. The call may be joined via telephone by dialing ...
... Highland Good Steward Management ("HGSM") today announced it ... investment adviser, as a sub adviser to Highland ... HGSM focuses on incorporating environmental, social ... William "Doug" Douglass III, co-founder of K2, said, ...
... Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce ... Administration (FDA) Level II Baseline Inspection and received a ... standard for the FDA to periodically perform unannounced inspections ... the FDA validates the Company,s quality system and its ...
Cached Medicine News:Health News:Kidney Care Partners Raises Alarm on Racial Disparities in Kidney Disease; Joins With National Minority Quality Forum to Educate Public, Congress During National Kidney Month 2Health News:Kidney Care Partners Raises Alarm on Racial Disparities in Kidney Disease; Joins With National Minority Quality Forum to Educate Public, Congress During National Kidney Month 3Health News:Sysmex America Introduces On Demand Middleware Training Tool 2Health News:Motorcycle Cancer Risk: Motorcycle Cop Cancer Concern from ELF EMFs Penetrating Motorcycle Seats 2Health News:K2 Advisors Named Investment Advisor by Highland Good Steward Management 2Health News:Solos Endoscopy, Inc. Successfully Completes FDA Inspection 2
(Date:7/28/2014)... , 28 luglio 2014 ResMed (NYSE: ... di prodotti per la cura dei disturbi respiratori del ... ha avuto un,ingiunzione permanente in Germania contro il produttore ... proibisce la vendita di apparecchiature da indossare in testa, ... e le maschere 220. La sentenza della Corte Regionale ...
(Date:7/28/2014)... 2014   Cardioxyl Pharmaceuticals, Inc. announced today ... CXL-1427, a novel potential treatment for acute decompensated heart ... company has now initiated dosing of hospitalized patients with ... designed to further evaluate the drug,s safety and tolerability ... Phase I clinical trial evaluated the safety and tolerability ...
(Date:7/28/2014)... CLARA, Calif. , July 28, 2014  ProteinSimple ... assay for the Simple Western. This new assay allows users ... For the first time, Simple Western users can analyze ... The Simple Western has changed protein analysis as ... hassles of Western blot protocols - no messy gels, ...
Breaking Medicine Technology:ResMed riceve un'ingiunzione permanente contro APEX in Germania, continua a far valere i propri diritti per i brevetti in Europa 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2ProteinSimple Says "Never Run a Gel Again!" 2
... California Cryobank (CCB), the nation,s leading ... branch in Indianapolis, IN.  In conjunction with General ... York, Cambridge, and Palo Alto as California Cryobank,s sixth ... HCLD(ABB), and John Critser, PhD., General BioTech is a ...
... with active moderate to severe rheumatoid arthritis (RA) inadequately ... (Humira ® ) and who were actively switched to ... at week 10, and sustained response through week 26 ... from the RESTART study were presented for the first ...
Cached Medicine Technology:Nation's Leading Sperm Bank Opens Branch in Indianapolis, IN 2New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 2New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 3New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 4New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 5New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 6New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE® After Inadequate Response to Enbrel® or Humira® Demonstrate Marked Clinical Improvement 7
... is for arthroscopic and open soft tissue repair ... procedural steps. It may be used with ... in conjunction with,anchors or screws (including suture pre-assembled ... tip permits the placement of a variety of ...
Knot pusher/suture retriever...
... The RC Retractor comes ... allow for superficial or deep ... Retractor permits retraction in three ... inferior. The fiber optic ...
Shoulder rasp...
Medicine Products: